Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944253 | 0.92 | TP53 (0.53) | FYNSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1945560 | 0.90 | MAPT (0.49) | FYNSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL1946451 | 0.90 | FYN (0.47) | FYNSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1944445 | 0.89 | FYN (0.47) | FYNSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1945204 | 0.89 | FYN (0.66) | FYNTTK | |
| SCHEMBL1945164 | 0.88 | FYN (0.46) | FYNTP53TTKMAPT | |
| SCHEMBL1944969 | 0.88 | F2RL3 (0.50) | FYNKDM4EF2RL3CCNKCDK9 | |
| SCHEMBL1945127 | 0.88 | F2RL3 (0.50) | FYNMAPTF2RL3CCNKCDK9 | |
| SCHEMBL1945884 | 0.87 | FYN (0.45) | FYNSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL1944873 | 0.87 | F2RL3 (0.50) | FYNNPC1RAB9AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | claimed |
| EP-2193133-B1 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-19 | — | — | EP | disclosed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8563550-B2 | Imidazolothiadiazoles for use as protein kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) | 2013-10-22 | — | — | US | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-08-04 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2193133-A2 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009040552-A2 | SUBSTITUTED IMIDAZO (2, 1-B) -1, 3, 4-THIAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 383/4885SMN1; SMN2 3346/4885NPC1 2895/4885 |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885SMN1; SMN2 4370/4885NPC1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.